Neuromyelitis Optics Therapy; Alleviate the Symptoms of Neuromyelitis Optica Disorder

Neuromyelitis optics therapy or therapies are used for the treatment of neuromyelitis optica disorder, as there is no cure for neuromyelitis optica disorder. Such therapies are used to treat acute attack of relapses and to reduce symptoms of the disease. Neuromyelitis optica is a rare condition where the immune system damages the spinal cord and the nerves of the eyes (optic nerves). Women are affected by this condition more frequently than men. There is no cure but there medicines and treatments may inhibit future disease flares.

In June 2019, the U.S. Food and Drug Administration (FDA) approved Soliris (eculizumab) injection for the treatment of neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. In the United States, neuromyelitis optica disorder prevalence is estimated to be around 1% to 2% that of multiple sclerosis, suggesting that there may be 4000 to 8000 patients. Moreover, the symptoms of neuromyelitis optica disorder are usually severe than multiple sclerosis.

Multiple sclerosis episodes are mild and patients may or may not accumulate disabilities, but neuromyelitis optica episodes can have debilitating and irreversible effects, and can also lower life expectancy. Neuromyelitis optica disorder treatment involves neuromyelitis optics therapy or therapies to reverse recent symptoms and prevent future attacks. MRI (Magnetic resonance imaging) is the choice of diagnostic method for neuromyelitis optica.

People with neuromyelitis optica experience symptoms such as muscle weakness, paralysis, and blindness. Moreover, people with neuromyelitis optica can have problem with eyesight particularly night blindness mobility problems including paralysis with transverse myelitis. Neuromyelitis optics therapy or therapies are extensively used in the treatment of acute attack of relapses and to reduce symptoms of the disease. A relapse can take from several hours up to days to develop.

Moreover, a blood test known as NMO-IgG blood test is positive in 70% of patients diagnosed with neuromyelitis optica. This has become an important marker for the disease and has helped improve understanding of this disorder.